TLR7 Activation of Macrophages by Imiquimod Inhibits HIV Infection through Modulation of Viral Entry Cellular Factors
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
TLR7 Activation of Macrophages by Imiquimod Inhibits HIV Infection through Modulation of Viral Entry Cellular Factors
Authors
Keywords
-
Journal
Biology-Basel
Volume 10, Issue 7, Pages 661
Publisher
MDPI AG
Online
2021-07-14
DOI
10.3390/biology10070661
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Recent trends in the development of Toll-like receptor 7/8-targeting therapeutics
- (2021) Xuan Huang et al. Expert Opinion on Drug Discovery
- Structural and functional understanding of the toll‐like receptors
- (2021) Jinta Asami et al. PROTEIN SCIENCE
- HIV infection suppresses TLR3 activation‐mediated antiviral immunity in microglia and macrophages
- (2020) Hang Liu et al. IMMUNOLOGY
- Agonist and antagonist ligands of toll-like receptors 7 and 8: Ingenious tools for therapeutic purposes
- (2020) Cindy Patinote et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Pattern Recognition Receptor Ligands as an Emerging Therapeutic Agent for Latent HIV-1 Infection
- (2020) Shokichi Takahama et al. Frontiers in Cellular and Infection Microbiology
- Imiquimod - A toll like receptor 7 agonist - Is an ideal option for management of COVID 19
- (2020) Athina Angelopoulou et al. ENVIRONMENTAL RESEARCH
- Detection of Viral Infections by Innate Immunity
- (2020) Michael Carty et al. BIOCHEMICAL PHARMACOLOGY
- Intranasal and epicutaneous administration of Toll-like receptor 7 (TLR7) agonists provides protection against influenza A virus-induced morbidity in mice
- (2019) Eunice E. To et al. Scientific Reports
- Determinants of HIV-1 reservoir size and long-term dynamics during suppressive ART
- (2019) Nadine Bachmann et al. Nature Communications
- The HIV Reservoir in Monocytes and Macrophages
- (2019) Michelle E. Wong et al. Frontiers in Immunology
- Interleukin-10 polymorphisms and susceptibility to ARV associated hepatotoxicity
- (2019) HariOm Singh et al. MICROBIAL PATHOGENESIS
- The Role of Macrophages in HIV-1 Persistence and Pathogenesis
- (2019) Zita Kruize et al. Frontiers in Microbiology
- Intercellular communication for innate immunity
- (2017) Tan A. Nguyen et al. MOLECULAR IMMUNOLOGY
- The Toll for Trafficking: Toll-Like Receptor 7 Delivery to the Endosome
- (2017) Carlene Petes et al. Frontiers in Immunology
- TLR7 Agonist GS-9620 Is a Potent Inhibitor of Acute HIV-1 Infection in Human Peripheral Blood Mononuclear Cells
- (2016) Rujuta A. Bam et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Resistance of Transmitted Founder HIV-1 to IFITM-Mediated Restriction
- (2016) Toshana L. Foster et al. Cell Host & Microbe
- TLR7/8 agonist induces a post-entry SAMHD1-independent block to HIV-1 infection of monocytes
- (2016) Henning Hofmann et al. Retrovirology
- Activation of NF- B via Endosomal Toll-Like Receptor 7 (TLR7) or TLR9 Suppresses Murine Herpesvirus 68 Reactivation
- (2014) F. Haas et al. JOURNAL OF VIROLOGY
- Gardiquimod: A Toll-Like Receptor-7 Agonist That Inhibits HIV Type 1 Infection of Human Macrophages and Activated T Cells
- (2013) Maarten Buitendijk et al. AIDS RESEARCH AND HUMAN RETROVIRUSES
- Immune activation of human brain microvascular endothelial cells inhibits HIV replication in macrophages
- (2013) J. Li et al. BLOOD
- Efficient infection, activation, and impairment of pDCs in the BM and peripheral lymphoid organs during early HIV-1 infection in humanized rag2-/- C-/- mice in vivo
- (2011) L. Zhang et al. BLOOD
- HIV infection of dendritic cells subverts the IFN induction pathway via IRF-1 and inhibits type 1 IFN production
- (2011) A. N. Harman et al. BLOOD
- Toll-like Receptors and Their Crosstalk with Other Innate Receptors in Infection and Immunity
- (2011) Taro Kawai et al. IMMUNITY
- Lipopolysaccharide (LPS) down-regulates CD4 expression in primary human macrophages through induction of endogenous tumour necrosis factor (TNF) and IL-1β
- (2010) G. HERBEIN et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Intracellular Toll-like Receptors
- (2010) Amanda L. Blasius et al. IMMUNITY
- Human CD14dim Monocytes Patrol and Sense Nucleic Acids and Viruses via TLR7 and TLR8 Receptors
- (2010) Jérôme Cros et al. IMMUNITY
- A critical function of toll-like receptor-3 in the induction of anti-human immunodeficiency virus activities in macrophages
- (2010) Yu Zhou et al. IMMUNOLOGY
- Suppressor of Cytokine Signaling 3 Inhibits Antiviral IFN- Signaling To Enhance HIV-1 Replication in Macrophages
- (2010) L. N. Akhtar et al. JOURNAL OF IMMUNOLOGY
- A Succession of Mechanisms Stimulate Efficient Reconstituted HIV-1 Minus Strand Strong Stop DNA Transfer†
- (2009) Min Song et al. BIOCHEMISTRY
- Imiquimod 5% cream for external genital or perianal warts in human immunodeficiency virus-positive patients treated with highly active antiretroviral therapy: an open-label, noncomparative study
- (2009) P. Saiag et al. BRITISH JOURNAL OF DERMATOLOGY
- Human Immunodeficiency Virus Type 1 Mediates Global Disruption of Innate Antiviral Signaling and Immune Defenses within Infected Cells
- (2009) B. P. Doehle et al. JOURNAL OF VIROLOGY
- Imiquimod Leads to a Decrease of Human Papillomavirus DNA and to a Sustained Clearance of Anal Intraepithelial Neoplasia in HIV-Infected Men
- (2008) Alexander Kreuter et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
- Strand transfer events during HIV-1 reverse transcription
- (2008) Vandana Purohit Basu et al. VIRUS RESEARCH
- HIV-1 accessory proteins VPR and Vif modulate antiviral response by targeting IRF-3 for degradation
- (2007) Atsushi Okumura et al. VIROLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started